Literature DB >> 23922481

FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Zhen Wang1, Jun-Qiang Chen, Jin-Lu Liu, Xin-Gan Qin, Yuan Huang.   

Abstract

AIM: To investigate the potential role of positron emission tomography (PET) in the diagnosis, staging and prognosis predicting of pancreatic carcinoma (PC).
METHODS: A systematic review of relevant literatures in PubMed, Embase and Cochrane Library was performed. The sensitivity and specificity of diagnostic and staging studies, and HRs for prognosis predicting studies were pooled. The bivariate model was used for diagnostic studies and the random-effect model for prognostic studies. Heterogeneity between included studies was tested using χ(2) test, and subgroup analysis was performed to explain the heterogeneities. All of the calculations were performed using Stata version 11.0.
RESULTS: A total of 39 studies were included. The pooled sensitivity of PET in diagnosing PC (30 studies, 1582 patients), evaluating N stating (4 studies, 101 patients) and liver metastasis (7 studies, 316 patients) were 0.91 (95%CI: 0.88-0.93), 0.64 (95%CI: 0.50-0.76), and 0.67 (95%CI: 0.52-0.79), respectively; and the corresponding specificity was 0.81 (95%CI: 0.75-0.85), 0.81 (95%CI: 0.25-0.85), and 0.96 (95%CI: 0.89-0.98), respectively. In prognosis analysis (6 studies, 198 patients), significant difference of overall survival was observed between high and low standardized uptake value groups (HR = 2.39, 95%CI: 1.57-3.63). Subgroup analysis showed that PET/CT was more sensitive than PET alone in evaluating liver metastasis of PC, 0.82 (95%CI: 0.48-0.98) and 0.67 (95%CI: 0.52-0.79), respectively.
CONCLUSION: PET can be used as a valuable diagnostic and predictive tool for PC, but its effect in the staging of PC remains indeterminate.

Entities:  

Keywords:  Diagnosis; Meta-analysis; Pancreatic carcinoma; Positron emission tomography; Prognosis; Staging

Mesh:

Substances:

Year:  2013        PMID: 23922481      PMCID: PMC3732856          DOI: 10.3748/wjg.v19.i29.4808

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  59 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer.

Authors:  Gaia Grassetto; Domenico Rubello
Journal:  Am J Clin Oncol       Date:  2011-04       Impact factor: 2.339

3.  Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.

Authors:  Kentaro Takanami; Tomomichi Hiraide; Masashi Tsuda; Yasuhiro Nakamura; Tomohiro Kaneta; Kei Takase; Hiroshi Fukuda; Shoki Takahashi
Journal:  Ann Nucl Med       Date:  2011-05-03       Impact factor: 2.668

4.  Diagnosis of pancreatic carcinoma: role of FDG PET.

Authors:  M T Keogan; D Tyler; L Clark; M S Branch; V G McDermott; D M DeLong; R E Coleman
Journal:  AJR Am J Roentgenol       Date:  1998-12       Impact factor: 3.959

5.  Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer.

Authors:  A Quon; S T Chang; F Chin; A Kamaya; D W Dick; B W Loo; S S Gambhir; A C Koong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-25       Impact factor: 9.236

6.  Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.

Authors:  T Inokuma; N Tamaki; T Torizuka; Y Magata; M Fujii; Y Yonekura; T Kajiyama; G Ohshio; M Imamura; J Konishi
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

7.  A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Authors:  Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

8.  18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Cosimo Sperti; Sergio Bissoli; Claudio Pasquali; Laura Frison; Guido Liessi; Franca Chierichetti; Sergio Pedrazzoli
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

9.  FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.

Authors:  Mariëtte C A van Kouwen; Jan B M J Jansen; Harry van Goor; Steve de Castro; Wim J G Oyen; Joost P H Drenth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-12       Impact factor: 9.236

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  34 in total

1.  Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-20       Impact factor: 9.236

2.  A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables.

Authors:  Mireia Crispin-Ortuzar; Jeho Jeong; Andrew N Fontanella; Joseph O Deasy
Journal:  Phys Med Biol       Date:  2017-01-31       Impact factor: 3.609

Review 3.  The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.

Authors:  Tong Dai; Elizabeta Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 4.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

5.  Functional expression of sodium-glucose transporters in cancer.

Authors:  Claudio Scafoglio; Bruce A Hirayama; Vladimir Kepe; Jie Liu; Chiara Ghezzi; Nagichettiar Satyamurthy; Neda A Moatamed; Jiaoti Huang; Hermann Koepsell; Jorge R Barrio; Ernest M Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 6.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 7.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

8.  Synthesis, quality control and determination of metallic impurities in 18F-fludeoxyglucose production process.

Authors:  Krzysztof Kilian; Bartłomiej Chabecki; Justyna Kiec; Agnieszka Kunka; Barbara Panas; Maciej Wójcik; Anna Pękal
Journal:  Rep Pract Oncol Radiother       Date:  2014-04-16

9.  Mediastinum metastasis in a post-surgical pancreatic cancer patient successfully confirmed with endoscopic ultrasonography.

Authors:  Hong-Tao Wei; Guang-Yong Chen; Peng Li
Journal:  World J Emerg Med       Date:  2021

Review 10.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.

Authors:  Naveen M Kulkarni; Erik V Soloff; Parag P Tolat; Guillermo P Sangster; Jason B Fleming; Olga R Brook; Zhen Jane Wang; Elizabeth M Hecht; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Lorenzo Mannelli; Avinash R Kambadakone; Eric P Tamm
Journal:  Abdom Radiol (NY)       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.